JPRN-jRCTs032220491
Completed
未知
An exploratory study on the effectiveness, usefulness, and safety of dietary management apps (Glucose Flight) in adult type 2 diabetic patients receiving insulin treatment
Ishii Hideto0 sites8 target enrollmentDecember 7, 2022
ConditionsType 2 diabetic
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetic
- Sponsor
- Ishii Hideto
- Enrollment
- 8
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients who are using insulin in the diagnosis of type 2 diabetes
- •2\) Patients with HbA1c \>\=7\.0% and \<\=10\.0% at \-8 weeks (retrospective data)
- •3\) Body Mass Index (BMI): Patients with BMI of more than 18\.5 kg/m2 and less than 35\.0 kg/m2
- •4\) Age at the time of obtaining consent: Patients over 20 years of age
- •5\) Gender: Regardless
- •6\) Patients for whom written consent has been obtained to participate in this study by their own free will
Exclusion Criteria
- •1\) Patients with type 1 diabetes
- •2\) Patients with steroid diabetes
- •3\) Pregnant patients
- •4\) Patients with diabetic nephropathy Stage 3\-5
- •5\) Patients currently diagnosed with cancer and undergoing treatment
- •6\) Patients with hemoglobin less than 11\.0 g/dL within 1 year before informed consent
- •7\) Patients who received a blood transfusion within one month
- •8\) Patients who plan to receive blood transfusions during clinical trials
- •9\) Furthermore, patients whose participation in this study is inappropriate by the principal or sub investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.Chronic spontaneous urticaria and the following skin disorders:1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermatitis, dyshidrotic eczema, asteatotic eczema, lichen simplex chronicus).2 - Prurigo (acute prurigo, subacute prurigo, chronic prurigo).3 - Cutaneous pruritus (systemic cutaneous pruritus, local cutaneous pruritus).MedDRA version: 19.0Level: HLTClassification code 10012435Term: Dermatitis and eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10037083Term: PrurigoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2016-001505-17-ESFAES FARMA, S.A.115
Active, not recruiting
Phase 1
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.EUCTR2016-001505-17-HUFAES FARMA, S.A.115
Not yet recruiting
Phase 1
Exploratory Research on the Efficacy Evaluation of Electroacupuncture in the Treatment of Cerebral Apoplexy and Paralysis Stage Based on the Theory of Treating Flaccid Paralysis by Yangming AStrokeITMCTR2100005445Huashan Hospital,Fudan University
Completed
Not Applicable
Examination of the effectiveness of Quasi-particle accelerator (QPA) for fibromyalgiafibromyalgiaJPRN-UMIN000044620Tokushima University3
Active, not recruiting
Phase 1
The exploratory study of EFE in COVID-19 patientsCOVID-19JPRN-jRCT2031210063Odaguchi Hiroshi156